Natus Medical (BABY) Lifted to “Hold” at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Natus Medical (NASDAQ:BABY) from a sell rating to a hold rating in a research note issued to investors on Friday.

Several other equities analysts also recently commented on BABY. Zacks Investment Research downgraded Natus Medical from a hold rating to a strong sell rating in a research report on Friday, October 26th. BidaskClub upgraded Natus Medical from a hold rating to a buy rating in a research report on Thursday, August 2nd. Finally, Roth Capital set a $36.00 target price on Natus Medical and gave the stock a buy rating in a research report on Thursday, October 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $42.50.

Natus Medical stock opened at $33.39 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.62 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.15 billion, a P/E ratio of 23.43 and a beta of 0.54. Natus Medical has a one year low of $27.69 and a one year high of $41.55.

Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.42 by ($0.02). The company had revenue of $130.60 million for the quarter, compared to the consensus estimate of $132.92 million. Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. Natus Medical’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.40 EPS. On average, equities research analysts forecast that Natus Medical will post 1.48 EPS for the current fiscal year.

In other Natus Medical news, insider Jonathan Kennedy sold 47,600 shares of Natus Medical stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $36.85, for a total value of $1,754,060.00. Following the completion of the transaction, the insider now owns 161,628 shares in the company, valued at approximately $5,955,991.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its position in Natus Medical by 4.6% in the 3rd quarter. BlackRock Inc. now owns 5,013,693 shares of the medical equipment provider’s stock valued at $178,739,000 after purchasing an additional 220,521 shares during the last quarter. Janus Henderson Group PLC raised its position in Natus Medical by 14.6% in the 3rd quarter. Janus Henderson Group PLC now owns 3,111,761 shares of the medical equipment provider’s stock valued at $110,934,000 after purchasing an additional 396,772 shares during the last quarter. Eagle Asset Management Inc. raised its position in Natus Medical by 6.8% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,924,407 shares of the medical equipment provider’s stock valued at $68,605,000 after purchasing an additional 123,132 shares during the last quarter. Carillon Tower Advisers Inc. bought a new position in Natus Medical in the 2nd quarter valued at $41,626,000. Finally, Voce Capital Management LLC raised its position in Natus Medical by 9.7% in the 2nd quarter. Voce Capital Management LLC now owns 725,109 shares of the medical equipment provider’s stock valued at $25,016,000 after purchasing an additional 64,308 shares during the last quarter. Hedge funds and other institutional investors own 97.72% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: Book Value Per Share – BVPS

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply